Resistance to CDK4/6 inhibitors in breast cancer is increasingly linked to hormonal pathway rewiring and transcriptional reprogramming, exemplified by hormone receptor (HR) loss and AP-1 overexpression. Here, FOS is linked to breast carcinoma.